NCT04629677 Evaluation of Portal Vein Stenting in Patients With Portal Vein Stenosis and Gastrointestinal Cancers
| NCT ID | NCT04629677 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Malignant Digestive System Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2019-04-02 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2019-04-02 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study collects information about the safety and effect of portal vein stenting in gastrointestinal cancer patients with portal vein stenosis. This study may help researchers learn how long the portal vein stays open and free from blockage and the effects of portal vein stenting on patients' overall well-being.
Eligibility Criteria
Inclusion Criteria: * COHORT A: All patients will undergo initial staging and treatment as per the institution standard of care. Patients will be considered eligible for porto-mesenteric venous stenting (PVS) if: * There is \> 75% porto-mesenteric venous stenosis in either main portal vein (PV), left PV, right PV, or the superior mesenteric vein (SMV), even in absence of symptoms of portal hypertension * Patients presented with any degree of vascular narrowing of said vessels and symptomatic portal hypertension including variceal bleeding, refractory ascites, abdominal pain, intestinal edema, or diarrhea after exclusion of tumor-related causes as direct tumor invasion or peritoneal dissemination * COHORT B: Patients who have thrombosis/stenosis of the main portal vein but who did not undergo stenting
Contact & Investigator
Joshua D Kuban
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT04629677 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Malignant Digestive System Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04629677 currently recruiting?
Yes, NCT04629677 is actively recruiting participants. Contact the research team at jdkuban@mdanderson.org for enrollment information.
Where is the NCT04629677 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT04629677 clinical trial?
NCT04629677 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Joshua D Kuban at M.D. Anderson Cancer Center. The trial plans to enroll 150 participants.